Drug recall · August 21, 2013
Rifadin recall
Why: Subpotent Drug: During review of retain samples, the manufacturer observed low fill in some capsules, which was related to an issue detected with the encapsulating equipment.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Rifadin (rifampin) capsules, USP, 150 mg, 100-count capsules per bottle, Manufactured by: Fabrique par Sanofi-Aventis Canada Inc., Laval, Quebec, Canada H7L4A8, DIN # 02091887
- Lots / codes
Lot # 3099036, Exp 03/2014
- Quantity
- 998 Bottles
- Company
- Sanofi-Synthelabo, Laval
- Distribution
- Canada
- Initiated
- February 26, 2013 · Voluntary: Firm initiated
- Classified
- August 13, 2013
- Reported
- August 21, 2013
- Ended
- June 6, 2014
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Rifampin
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.